Williamstown, MA -- (SBWIRE) -- 04/02/2012 -- This analysis examines the historical and forecast performance for Amylin in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.
- Gain insight into Amylin's strategic outlook across the next 6 years
- Analysis of strategically important company products
Strategic evaluation of Amylin's outlook for the next six years. Assessment of key strengths, weaknesses, opportunities and threats and appraisal of the company's product portfolio, pipeline and commercial relationships.
View Full Report Details and Table of Contents
Reasons to Get this Report:
- Assess the prospects of the recently FDA-approved Bydureon, a once-weekly follow on to Byetta
- Examine the potential repercussions of the termination of Amylin's exenatide partnership with Eli Lilly
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Amylin Pharmaceuticals, Inc. - Strategy, SWOT, and Corporate Finance Report
- Amylin Pharmaceuticals, Inc. - Strategy and SWOT Report
- Amylin Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011
- Amylin Pharmaceuticals - Product Pipeline Review - Q4 2010
- MAP Pharmaceuticals: PharmaVitae Report
- Amylin Pharmaceuticals, Inc. (AMLN) - Financial and Strategic SWOT Analysis Review
- Amylin Pharmaceuticals Inc - Deals & Alliances Report
- Eli Lilly and Company (LLY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- King Pharmaceuticals, Inc - Strategy, SWOT, and Corporate Finance Report
- Endo Pharmaceuticals Holdings Inc. - Strategy, SWOT, and Corporate Finance Report